Hormonal Contraceptives Differentially Impact Breast Cancer Risk: New Large-Scale Study Highlights Significant Variations by Formulation

A recent extensive population-based study involving more than two million adolescent girls and women between the ages of 13 and 49 in Sweden provides fresh insights into how different hormonal contraceptives impact breast cancer risk. Published on November 4, 2025, in JAMA Oncology, the study reveals that not all hormonal contraceptives carry the same level of breast cancer risk, with desogestrel-containing formulations—particularly progestin-only types—showing the highest increase in risk. The findings open an important dialogue for personalized contraceptive counseling and informed decision-making regarding breast cancer risk management.

Key Findings and Study Details
The Swedish cohort study meticulously analyzed health records from 2006 to 2019, following 2,095,130 individuals with no prior cancer or relevant reproductive surgeries. Over a mean follow-up of 10 years, 1,284,613 participants used hormonal contraceptives, while breast cancer diagnosis occurred in 8,485 users versus 7,900 non-users.​

Overall, any use of hormonal contraceptives was linked to a 24% increased relative risk of breast cancer compared to never-users, translating to approximately one additional breast cancer case per 7,752 users. The risk varied notably by contraceptive type:​

• Progestin-only contraceptives showed a 21% increased risk.

• Combined hormonal contraceptives (estrogen plus progestin) showed a 12% increased risk.

• The differential translated to one extra breast cancer case per 8,572 progestin-only users, versus one per 14,417 combined-formulation users.​

Further classification by specific progestins revealed that oral desogestrel-only contraceptives corresponded with an 18% increased breast cancer risk; when combined with estrogen in oral forms or delivered via implants containing etonogestrel (desogestrel’s active metabolite), risk rose to 19% and 22%, respectively. Conversely, formulations containing levonorgestrel showed lower but still elevated risks around 9-13%.​

Duration of use mattered substantially. Individuals using hormonal contraceptives for less than a year experienced an 11% increased risk, rising to 21% for one to five years, and 34% for five to ten years of use. Long-term users of desogestrel-containing contraceptives faced nearly a 50% increased risk, highlighting the importance of exposure time in cancer risk.​

Expert Perspectives
Fatemeh Hadizadeh, MD, PhD, lead author and researcher at Uppsala University, emphasized that these novel findings on desogestrel’s association with increased breast cancer risk warrant cautious interpretation and require confirmation by independent studies before altering clinical guidelines. She advocates for individualized contraceptive counseling, especially for women with known genetic breast cancer risks, such as BRCA1/2 mutation carriers, or strong family histories. She noted that although risk increases exist, absolute risks remain low, and risk declines after cessation of contraceptive use.​

Åsa Johansson, senior author and research group leader at Uppsala University and SciLifeLab, pointed out the complex balance in recommending hormonal contraceptives to BRCA mutation carriers. While these individuals have heightened breast cancer risk, hormonal contraceptives remain the most protective factor against ovarian cancer, which is highly lethal, underscoring the need for nuanced clinical decisions.​

Context and Background
Hormonal contraceptives have long been recognized to slightly increase breast cancer risk, with previous research primarily focusing on combined oral contraceptives. Studies have reported varied risk estimates, usually between 8% and 24% increased relative risk, confirming a modest but consistent association. However, the distinct risk pattern related to specific formulations, particularly individual progestins, had not been conclusively established until now.​

This Swedish study is unprecedented in size and detail, leveraging the country’s comprehensive national health registers covering over two million women and their contraceptive histories with long-term cancer incidence data. Previous meta-analyses have similarly highlighted the dose-duration relationship and some risk variation by contraceptive type, yet this study sharpens the focus on hormonal formulation nuances.​

Implications for Public Health
The study’s findings underscore the need for healthcare professionals to provide targeted counseling that incorporates individualized breast cancer risk profiles and contraceptive selection. For women at higher risk or with family history concerns, selective avoidance of desogestrel-containing progestin-only contraceptives and consideration of safer options like levonorgestrel-based or certain combined hormonal contraceptives may be warranted.​

Moreover, patients should be informed that although the relative risk increases are notable, the absolute risk for most women remains low. The study reinforces the importance of weighing benefits against risks—including contraceptives’ efficacy in preventing unintended pregnancy and their protective effect against ovarian and endometrial cancers, especially in susceptible populations.

Limitations and Balanced Reporting
As an observational cohort study, the research cannot establish direct causality due to potential confounding factors such as lifestyle, family history, and genetic predispositions not fully accounted for. The authors caution that findings need validation in other populations and clinical settings. Additionally, although relative risks are increased, breast cancer remains a complex, multifactorial disease, and hormonal contraceptive use is one among many environmental and genetic risk factors.​

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.